Zhongzheng Smart Finance News, Fosun Pharma (600196) announced in the evening on December 3, 2025, that its controlling subsidiary, Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd. (hereinafter referred to as "Fosun Pharma Industrial"), has received approval from the National Medical Products Administration (NMPA) to conduct clinical trials for its self-developed oral small molecule innovative drug, FXS0887 tablets, for the treatment of advanced malignant solid tumors. Fosun Pharma Industrial plans to initiate Phase I clinical trials in China when conditions are met.
According to the announcement, FXS0887 can specifically inhibit the activity of the ATR (Ataxia Telangiectasia and Rad3-related) kinase, thereby inhibiting the malignant proliferation of tumor cells by interfering with cell cycle regulation and DNA damage repair-related pathways. Current preclinical studies have shown that the drug exhibits good antitumor activity in a variety of tumor models, with small off-target risk and good safety.
The announcement stated that as of October 2025, the company's cumulative R&D investment for FXS0887 was approximately RMB 44 million (unaudited). As of the announcement date, no small molecule inhibitor single-agent or combination therapy with the same target has been approved for marketing globally.

https://finance.eastmoney.com/a/202512033581684833.html